Longevity & AgingAstraZeneca's GLP-1 Pill Cuts Weight 11% and Lowers Blood Sugar in Phase 2 Trials
AstraZeneca's investigational oral GLP-1 drug elecoglipron showed promising results in two Phase 2 trials. In the VISTA obesity trial, patients on the highest dose lost 11.2% of their body weight over 36 weeks. In the SOLSTICE diabetes trial, the highest dose reduced A1C — a key blood sugar marker — by 1.74 percentage points over 26 weeks, outperforming oral Ozempic's 1.32-point reduction in a comparator group. These results position elecoglipron as a potential competitor in the growing oral GLP-1 market, though direct comparisons to approved pills like Eli Lilly's Foundayo are difficult given differences in trial phase and duration. The drug is not yet approved, and larger Phase 3 trials will be needed to confirm efficacy and safety.
